hotspot -WSS

hotspot

author：fashion 2025-10-02 09:45:18 - browse：1983

The experimental Alzheimer’s drug lecanemab, hailed after it slowed patients’ cognitive decline in a clinical trial, may have contributed to the death in June of a patient in the study, STAT has learned.

One investigator on the study flagged the death, noting it came after the patient experienced bleeding in the brain, and concluded it was related to the drug, according to documents obtained by STAT. Eisai, the drugmaker behind lecanemab, disagreed, pointing to other possible factors, including a series of setbacks in preceding months — multiple falls, a heart attack, a respiratory infection, and mini-stroke-like events.

Though still under investigation, the death suggests that new medicines to treat Alzheimer’s, like medicines to treat anything else, will come with their own side effects and costs. It also raises the importance of waiting for the full lecanemab data before drawing conclusions based on the positive press release put out by Eisai and its partner Biogen last month.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Jerome Adams on the need for new antivirals for Covid
Next article： Listen: Wegovy in the brain & pivotal Alzheimer's data

leisure time

WSS

'Disease catastrophe' looms in Sudan as health conditions deteriorate, medics warn

Target recalls 2.2 million additional candles due to laceration, burn hazards

Novo acquires Inversago for up to $1 billion

Pharma budget tightening trickles down to Doximity

Whistleblower: Blue Cross Blue Shield evaded $170 million in taxes

FDA approves RSV monoclonal antibody for infants, toddlers

focus

hotspot

entertainment

The high cost of giving birth even with insurance

Why hospitals are withdrawing from US News rankings

FDA approval of Sarepta Duchenne genetic therapy gives me hope

NYC stabbing: Teen named, arraigned by District Attorney in O'Shae Sibley death

Jerome Adams on the need for new antivirals for Covid

Listen: Your guide to Wegovy's blockbuster heart study

Duchenne breakthrough therapy leaves behind pioneering families

Listen: Wegovy in the brain & pivotal Alzheimer's data

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

'Disease catastrophe' looms in Sudan as health conditions deteriorate, medics warn

explore

Startup Neumora takes a novel depression drug to Phase 3

Genentech weighs delaying cancer therapy after drug pricing law

Google and Epic fight stronger regulation of AI in health care

Kim Kardashian sparks debate on benefits of full

White House drug shortages task force keeps mum with Congress

Large hospital system sues Multiplan for low

entertainment

explore

leisure time

focus